{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:15:11Z","timestamp":1793837711308,"version":"4.6.1"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007083","name":"Orionin Tutkimuss\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007083","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004012","name":"Jane ja Aatos Erkon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008376","name":"Helsingin ja Uudenmaan Sairaanhoitopiiri","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017400","name":"Finnish Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007797","name":"Helsingin Yliopisto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007797","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004212","name":"P\u00e4ivikki ja Sakari Sohlbergin S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004212","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008397","name":"Suomen Tiedeseura","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors such as anti-PD-1 have revolutionized the field of oncology over the past decade. Nevertheless, the majority of patients do not benefit from them. Virotherapy is a flexible tool that can be used to stimulate and\/or recruit different immune populations. T-cell enabling virotherapy could enhance the efficacy of immune checkpoint inhibitors, even in tumors resistant to these inhibitors. The T-cell potentiating virotherapy used here consisted of adenoviruses engineered to express tumor necrosis factor alpha and interleukin-2 in the tumor microenvironment. To study virus efficacy in checkpoint-inhibitor resistant tumors, we developed an anti-PD-1 resistant melanoma model <jats:italic>in vivo<\/jats:italic>. In resistant tumors, adding virotherapy to an anti-PD-1 regimen resulted in increased survival (p=0.0009), when compared to anti-PD-1 monotherapy. Some of the animals receiving virotherapy displayed complete responses, which did not occur in the immune checkpoint-inhibitor monotherapy group. When adenoviruses were delivered into resistant tumors, there were signs of increased CD8 T-cell infiltration and activation, which - together with a reduced presence of M2 macrophages and myeloid-derived suppressor cells - could explain those results. T-cell enabling virotherapy appeared as a valuable tool to counter resistance to immune checkpoint inhibitors. The clinical translation of this approach could increase the number of cancer patients benefiting from immunotherapies.<\/jats:p>","DOI":"10.3389\/fimmu.2021.706517","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T12:54:50Z","timestamp":1627044890000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1"],"prefix":"10.3389","volume":"12","author":[{"given":"Victor","family":"Cervera-Carrascon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafne C. A.","family":"Quixabeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao M.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riikka","family":"Havunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Milenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Verhoeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Heini\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadia","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J.","family":"Garcia-Vallejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor W.","family":"van Beusechem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja D.","family":"de Gruijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aino","family":"Kalervo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvi","family":"Sorsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kanerva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akseli","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-018-06751-0","article-title":"Cancer Immunologists Scoop Medicine Nobel Prize","volume":"562","author":"Ledford","year":"2018","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejca.2019.04.035","article-title":"The Evolving Landscape of \u2018Next-Generation\u2019 Immune Checkpoint Inhibitors: A Review","volume":"117","author":"Mazzarella","year":"2019","journal-title":"Eur J Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00195","article-title":"Schenk E. A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-Small Cell Lung Cancer","volume":"9","author":"Pacheco","year":"2019","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/PPO.0000000000000246","article-title":"New Combination Strategies Using Programmed Cell Death 1\/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone","volume":"23","author":"Hu-Lieskovan","year":"2017","journal-title":"Cancer J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11040539","article-title":"Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review","volume":"11","author":"Longo","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_240837","article-title":"Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients","author":"Fares","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.immuni.2017.02.001","article-title":"Loss of PTEN Is Associated With Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma","volume":"46","author":"George","year":"2017","journal-title":"Immunity"},{"key":"B9","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary Resistance to PD-1 Blockade Mediated by JAK1\/2 Mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discovery"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e1445453","DOI":"10.1080\/2162402X.2018.1445453","article-title":"Complex Pattern of Immune Evasion in MSI Colorectal Cancer","volume":"7","author":"Ozcan","year":"2018","journal-title":"Oncoimmunology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e1261779","DOI":"10.1080\/2162402X.2016.1261779","article-title":"Adaptive Resistance to Anti-PD1 Therapy by Tim-3 Upregulation Is Mediated by the PI3K-Akt Pathway in Head and Neck Cancer","volume":"6","author":"Shayan","year":"2017","journal-title":"Oncoimmunology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0828","article-title":"Evolution of Neoantigen Landscape During Immune Checkpoint Blockade in Non-Small Cell Lung Cancer","volume":"7","author":"Anagnostou","year":"2017","journal-title":"Cancer Discovery"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10501","article-title":"Adaptive Resistance to Therapeutic PD-1 Blockade Is Associated With Upregulation of Alternative Immune Checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300108","article-title":"History of Oncolytic Viruses: Genesis to Genetic Engineering","volume":"15","author":"Kelly","year":"2007","journal-title":"Mol Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2017.11.006","article-title":"Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies","volume":"39","author":"Gujar","year":"2018","journal-title":"Trends Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000188","article-title":"Oncolytic Adenovirus Shapes the Ovarian Tumor Microenvironment for Potent Tumor-Infiltrating Lymphocyte Tumor Reactivity","volume":"8","author":"Santos","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1595582","article-title":"Oncolytic Adenoviruses: A Game Changer Approach in the Battle Between Cancer and the Immune System","volume":"19","author":"Cervera-Carrascon","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.240","article-title":"Effect of Genetic Modifications on Physical and Functional Titers of Adenoviral Cancer Gene Therapy Constructs","volume":"30","author":"Heinio","year":"2019","journal-title":"Hum Gene Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2009.56","article-title":"Ad5\/3-9hif-Delta24-VEGFR-1-Ig, an Infectivity Enhanced, Dual-Targeted and Antiangiogenic Oncolytic Adenovirus for Kidney Cancer Treatment","volume":"16","author":"Guse","year":"2009","journal-title":"Gene Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302517","article-title":"Combination of Gemcitabine and Ad5\/3-Delta24, A Tropism Modified Conditionally Replicating Adenovirus, for the Treatment of Ovarian Cancer","volume":"12","author":"Raki","year":"2005","journal-title":"Gene Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2009.103","article-title":"A Modified E2F-1 Promoter Improves the Efficacy to Toxicity Ratio of Oncolytic Adenoviruses","volume":"16","author":"Rojas","year":"2009","journal-title":"Gene Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0131242","DOI":"10.1371\/journal.pone.0131242","article-title":"Favorable Alteration of Tumor Microenvironment by Immunomodulatory Cytokines for Efficient T-Cell Therapy in Solid Tumors","volume":"10","author":"Tahtinen","year":"2015","journal-title":"PloS One"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.137","article-title":"Adenoviral Delivery of Tumor Necrosis Factor-Alpha and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma","volume":"24","author":"Siurala","year":"2016","journal-title":"Mol Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.omto.2016.12.004","article-title":"Oncolytic Adenoviruses Armed With Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy","volume":"4","author":"Havunen","year":"2017","journal-title":"Mol Ther Oncolytics"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0220-T","article-title":"Adenovirus Improves the Efficacy of Adoptive T-Cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor","volume":"3","author":"Tahtinen","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.omto.2020.03.003","article-title":"Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors","volume":"17","author":"Cervera-Carrascon","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.6152","article-title":"Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial","author":"Kelly","year":"2020","journal-title":"JAMA Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e1412902","DOI":"10.1080\/2162402X.2017.1412902","article-title":"TNFa and IL-2 Armed Adenoviruses Enable Complete Responses by Anti-PD-1 Checkpoint Blockade","volume":"7","author":"Cervera-Carrascon","year":"2018","journal-title":"Oncoimmunology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-14-0216","article-title":"Virotherapy With a Semliki Forest Virus-Based Vector Encoding IL12 Synergizes With PD-1\/PD-L1 Blockade","volume":"3","author":"Quetglas","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e1457596","DOI":"10.1080\/2162402X.2018.1457596","article-title":"Oncolytic Vaccines Increase the Response to PD-L1 Blockade in Immunogenic and Poorly Immunogenic Tumors","volume":"7","author":"Feola","year":"2018","journal-title":"Oncoimmunology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e1532763","DOI":"10.1080\/2162402x.2018.1532763","article-title":"Combination of Immunogenic Oncolytic Adenovirus ONCOS-102 With Anti-PD-1 Pembrolizumab Exhibits Synergistic Antitumor Effect in Humanized A2058 Melanoma huNOG Mouse Model","volume":"8","author":"Kuryk","year":"2019","journal-title":"Oncoimmunology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations Associated With Acquired Resistance to PD-1 Blockade in Melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-19-2062","article-title":"Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy","volume":"80","author":"T\u00e4htinen","year":"2020","journal-title":"Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1038\/s41467-021-23324-4","article-title":"Interpretation of T Cell States From Single-Cell Transcriptomics Data Using Reference Atlases","volume":"12","author":"Andreatta","year":"2021","journal-title":"Nat Commun"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2020.1737369","article-title":"Deciphering the Transcriptomic Landscape of Tumor-Infiltrating CD8 Lymphocytes in B16 Melanoma Tumors With Single-Cell RNA-Seq","volume":"9","author":"Carmona","year":"2020","journal-title":"Oncoimmunology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1172\/JCI90962","article-title":"The Role of the Complement System in Cancer","volume":"127","author":"Afshar-Kharghan","year":"2017","journal-title":"J Clin Invest"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1922-8","article-title":"B Cells and Tertiary Lymphoid Structures Promote Immunotherapy Response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830180221","article-title":"The Half-Lives of Serum Immunoglobulins in Adult Mice","volume":"18","author":"Vieira","year":"1988","journal-title":"Eur J Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s40425-019-0779-6","article-title":"Incidence Rates of Immune-Related Adverse Events and Their Correlation With Response in Advanced Solid Tumours Treated With NIVO or NIVO+IPI: A Systematic Review and Meta-Analysis","volume":"7","author":"Xing","year":"2019","journal-title":"J Immuno Ther Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2147\/OV.S145532","article-title":"Oncolytic Virus and PD-1\/PD-L1 Blockade Combination Therapy","volume":"7","author":"Chen","year":"2018","journal-title":"Oncolytic Virother"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1037058","article-title":"Oncolytic Viruses: From Bench to Bedside With a Focus on Safety","volume":"11","author":"Buijs","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2267","article-title":"Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma","volume":"24","author":"Gide","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"B45","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.tcb.2020.06.003","article-title":"The Roles of CD8(+) T Cell Subsets in Antitumor Immunity","volume":"30","author":"St Paul","year":"2020","journal-title":"Trends Cell Biol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01310","article-title":"Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors","volume":"9","author":"Weber","year":"2018","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.6049","article-title":"Correlation of Constitutive PD-1 Resistance in HNC With GM-CSF Expression and Presence of Myeloid Derived Suppressor Cells (MDSCs)","volume":"35","author":"Seiwert","year":"2017","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2018.00038","article-title":"Targeting Tumor-Associated Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors","volume":"6","author":"Cassetta","year":"2018","journal-title":"Front Cell Dev Biol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040798","article-title":"TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling","volume":"9","author":"Heini\u00f6","year":"2020","journal-title":"Cells"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1408","article-title":"PD-1hi Identifies a Novel Regulatory B-Cell Population in Human Hepatoma That Promotes Disease Progression","volume":"6","author":"Xiao","year":"2016","journal-title":"Cancer Discovery"},{"key":"B51","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.cell.2019.06.014","article-title":"Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold","volume":"178","author":"Vredevoogd","year":"2019","journal-title":"Cell"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99573","article-title":"Pancreatic Cancer Therapy With Combined Mesothelin-Redirected Chimeric Antigen Receptor T Cells and Cytokine-Armed Oncolytic Adenoviruses","volume":"3","author":"Watanabe","year":"2018","journal-title":"JCI Insight"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2018.10.005","article-title":"Abscopal Effect in Non-Injected Tumors Achieved With Cytokine-Armed Oncolytic Adenovirus","volume":"11","author":"Havunen","year":"2018","journal-title":"Mol Ther Oncolytics"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.706517\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T12:54:58Z","timestamp":1627044898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.706517\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":53,"alternative-id":["10.3389\/fimmu.2021.706517"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.706517","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"article-number":"706517"}}